A Lipid Nanoparticle System Improves siRNA Efficacy in RPE Cells and a Laser-Induced Murine CNV Model
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
PURPOSE: To explore the possibility of the PEGylated liposome-protamine-hyaluronic acid nanoparticles (PEG-LPH-NP) loaded with siRNA (PEG-LPH-NP-S) in ARPE19 cells and a laser-induced rat model for the treatment of choroidal neovascularization (CNV). METHODS: PEG-LPH-NP-S was characterized by dynamic light scattering and transmission electron microscopy (TEM). The encapsulation efficiency of siRNA in PEG-LPH-NP was analyzed by ultracentrifugation, whereas the protection of siRNA by PEG-LPH-NP was evaluated by electrophoresis. Human RPE cells (ARPE19) were used as the cell model for the studies of cellular uptake and the inhibition of VEGFR1 expression, visualized by a laser scanning confocal microscope. The area of CNV in the laser-induced rat model after intravitreous injection was measured. The distribution of the lipid nanoparticles in the retina after intravitreous administration was investigated by fluorescence microscopy. Finally, the TUNEL test and morphologic observation of the retina were conducted. RESULTS: It was indicated that PEG-LPH-NP-S was approximately 132 nm in particle size with a positive charge of approximately 20 mV, whereas the encapsulation efficiency of siRNA in PEG-LPH-NP was >95%. PEG-LPH-NP could protect the siRNA load and could facilitate the intracellular delivery of fluorescein-labeled siRNA to ARPE19 cells. VEGFR1 expression in ARPE19 cells could be inhibited, and the CNV area in the murine model could be reduced more effectively by PEG-LPH-NP-S compared with naked siRNA and by PEG-LPH-NP with negative siRNA. It seems that the toxicity of PEG-LPH-NP-S on the rat retina is low, based on the results of TUNEL testing and morphologic observation. CONCLUSIONS: PEG-LPH-NP may be a promising lipid nanoparticle system for the siRNA treatment of CNV.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, lipid-based transfection systems have shown success in their ability to transfer the target genes into retinal cells in several studies, and multiple lipid-based drugs for eye diseases are already available in the clinic35,79,87–91 and for the delivery of CRISPR or ribonucleoproteins for base editing.92,93”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [89]
Citations
Cites
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
Evidence for the role of proteoglycans in cation-mediated gene transfer.
Mislick, K. A., & Baldeschwieler, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12349 · Cited by 772
Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F., & Aigner, A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302425 · Cited by 716
Age-Related Macular Degeneration Is the Leading Cause of Blindness . . .
Bressler, N. M. (2004) · JAMA · doi:10.1001/jama.291.15.1900 · Cited by 684
Reich, S. J., Fosnot, J., Kuroki, A. M., Tang, W., Yang, X., Maguire, A. M., Bennett, J., & Tolentino, M. J. (2003) · PubMed · Cited by 486
Gene Silencing by Systemic Delivery of Synthetic siRNAs in Adult Mice
Sørensen, D. R., Leirdal, M., & Sioud, M. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00181-5 · Cited by 464
Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1
Shen, J., Samul, R., Silva, R. L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S. F., Zinnen, S., Kossen, K., Fosnaugh, K., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302641 · Cited by 307
Self-citation
Cited by
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Subrizi, A., del Amo, E. M., Korzhikov-Vlakh, V., Tennikova, T., Ruponen, M., & Urtti, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.001 · Cited by 239
Koo, H., Moon, H., Han, H., Na, J. H., Huh, M. S., Park, J. H., Woo, S. J., Park, K. H., Chan Kwon, I., Kim, K., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.01.030 · Cited by 214
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Nanotherapy for posterior eye diseases
Kaur, I. P., & Kakkar, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.031 · Cited by 175
Metadata
- Authors
- Liu, H.-A., Liu, Y.-L., Ma, Z.-Z., Wang, J.-C., & Zhang, Q.
- Affiliations
- Peking University (CN)
- From the Peking University Eye Center, Peking University Third Hospital, Peking University, Beijing, China; and
- the State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
- ORCID
- Zhang, Qiang
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2011-06-30
- Volume
- 52
- Issue
- 7
- Pages
- 4789
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W1970980357
- Cited by
- 97
- References
- 19
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 7 · 2020: 7 · 2019: 6 · 2018: 5 · 2017: 4 · 2016: 10 · 2015: 9 · 2014: 6 · 2013: 5 · 2012: 5
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- lipid nanoparticles, siRNA delivery, choroidal neovascularization, PEGylated liposomes, protamine, hyaluronic acid, intravitreal injection, nanoparticle toxicity, retinal distribution
- MeSH terms
- Animals, Cells, Cultured, Disease Models, Animal, Humans, Liposomes, Male, Microscopy, Fluorescence, Rats, Inbred BN, Treatment Outcome, Apoptosis, Microscopy, Confocal, Choroidal Neovascularization, In Situ Nick-End Labeling, RNA, Small Interfering, Vascular Endothelial Growth Factor Receptor-1, Microscopy, Electron, Transmission, Rats, Nanoparticles, Retinal Pigment Epithelium, Young Adult, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.